Cabio Financial Statements From 2010 to 2025

Stocks . China . 
Stock . Cabio Biotech Wuhan
688089 Stock   17.84  0.94  5.01%   
Cabio Biotech financial statements provide useful quarterly and yearly information to potential Cabio Biotech Wuhan investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cabio Biotech financial statements helps investors assess Cabio Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cabio Biotech's valuation are summarized below:
Gross Profit
179.6 M
Profit Margin
0.2269
Market Capitalization
3 B
Enterprise Value Revenue
5.6553
Revenue
506.1 M
We have found seventy-one available fundamental signals for Cabio Biotech Wuhan, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cabio Biotech Wuhan prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Cabio Biotech Total Revenue

353.07 Million

Check Cabio Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cabio Biotech's main balance sheet or income statement drivers, such as Tax Provision of 17.8 M, Net Interest Income of 1.7 M or Interest Expense of 856.9 K, as well as many indicators such as . Cabio financial statements analysis is a perfect complement when working with Cabio Biotech Valuation or Volatility modules.
  
This module can also supplement various Cabio Biotech Technical models . Check out the analysis of Cabio Biotech Correlation against competitors.

Cabio Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.2 B1.9 B928.5 M
Slightly volatile
Total Current Liabilities82.2 M129.3 M75.5 M
Slightly volatile
Total Stockholder Equity1.1 B1.7 B843.2 M
Slightly volatile
Retained Earnings291.8 M484.5 M200.4 M
Slightly volatile
Accounts Payable85.6 M81.5 M31.9 M
Slightly volatile
Cash458.3 M275.6 M271 M
Slightly volatile
Non Current Assets Total1.1 B1 B412.7 M
Slightly volatile
Non Currrent Assets Other22.2 M32.4 M14.3 M
Slightly volatile
Net Receivables149.9 M247 M117.9 M
Slightly volatile
Non Current Liabilities Total5.1 M4.7 M6.7 M
Slightly volatile
Inventory87.9 M129.5 M88.4 M
Very volatile
Other Current Assets61.9 M59 M23.6 M
Slightly volatile
Total Liabilities89.2 M135.2 M82.4 M
Slightly volatile
Short and Long Term Debt16.9 M10.9 M22.2 M
Slightly volatile
Total Current Assets790.9 M815.1 M556.7 M
Slightly volatile
Intangible Assets26.8 M47.2 M26.8 M
Pretty Stable
Other Current Liabilities295.6 K311.2 K3.5 M
Slightly volatile
Common Stock Shares Outstanding130.2 M193.6 M111.4 M
Slightly volatile
Net Invested Capital1.2 B1.7 B880.5 M
Slightly volatile
Net Working Capital779.8 M685.8 M514.1 M
Slightly volatile
Capital Stock135.4 M193.6 M111.7 M
Slightly volatile
Other Liabilities4.5 M3.3 M5.8 M
Slightly volatile
Net Tangible Assets1.5 B1.6 B1.3 B
Slightly volatile
Property Plant And Equipment Net370.6 M739.8 M266.8 M
Slightly volatile
Other Assets41.2 M35.6 M20.5 M
Slightly volatile
Property Plant And Equipment Gross610.7 M1.1 B506.6 M
Slightly volatile
Common Stock96 M108 M117.8 M
Slightly volatile
Property Plant Equipment286.3 M558.9 M240.3 M
Slightly volatile
Short Term Investments26.5 K27.9 K12.1 M
Slightly volatile
Capital Lease Obligations1 M595.4 K1.4 M
Slightly volatile
Deferred Long Term Liabilities1.6 M2.8 M865.5 K
Slightly volatile

Cabio Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision17.8 M15.7 M13.4 M
Slightly volatile
Selling General Administrative35.2 M44.9 M30.8 M
Slightly volatile
Total Revenue353.1 M510.4 M285.6 M
Slightly volatile
Gross Profit169.2 M216.4 M136.4 M
Slightly volatile
Operating Income96.8 M105.8 M75.5 M
Slightly volatile
Net Income From Continuing Ops102.3 M99.3 M76.5 M
Slightly volatile
EBIT80.5 M60.9 M88 M
Very volatile
Research Development25.5 M44.4 M21.3 M
Slightly volatile
Cost Of Revenue183.9 M294 M149.2 M
Slightly volatile
Total Operating Expenses256.3 M404.6 M210.2 M
Slightly volatile
Income Before Tax120.1 M115 M89.8 M
Slightly volatile
Net Income102.1 M105.1 M77 M
Slightly volatile
Interest Income3.2 M2.4 M1.7 M
Slightly volatile
EBITDA162 M121.3 M127.1 M
Slightly volatile
Reconciled Depreciation32.9 M55.6 M30.4 M
Slightly volatile
Other Operating Expenses3.8 M4.1 M4.8 M
Slightly volatile
Net Income Applicable To Common Shares88.3 M57.9 M107.2 M
Slightly volatile
Income Tax Expense15.8 M14 M19 M
Slightly volatile

Cabio Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation32.4 M55.6 M30.5 M
Slightly volatile
Dividends Paid35.7 M42.1 M22 M
Slightly volatile
Capital Expenditures359.4 M342.3 M101.7 M
Slightly volatile
Total Cash From Operating Activities123.2 M79.2 M92.1 M
Slightly volatile
Net Income102.1 M105.1 M77 M
Slightly volatile
End Period Cash Flow456.4 M275.6 M270 M
Slightly volatile
Begin Period Cash Flow483.9 M564.2 M277.5 M
Slightly volatile
Change To Operating Activities11.7 M13.2 M14.4 M
Slightly volatile
Other Cashflows From Investing Activities11.3 M10 M5.2 M
Slightly volatile

About Cabio Biotech Financial Statements

Cabio Biotech stakeholders use historical fundamental indicators, such as Cabio Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cabio Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cabio Biotech's assets and liabilities are reflected in the revenues and expenses on Cabio Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cabio Biotech Wuhan. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue510.4 M353.1 M
Cost Of Revenue294 M183.9 M

Currently Active Assets on Macroaxis

SSentinelOne
CRMSalesforce
MSFTMicrosoft
GOOGAlphabet Inc Class C
GMGeneral Motors

Other Information on Investing in Cabio Stock

Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY